Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
$70.87 +0.49 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$70.72 -0.15 (-0.21%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, ONC, BNTX, TEVA, and SMMT

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs.

Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Novo Nordisk A/SOutperform Votes
434
61.74%
Underperform Votes
269
38.26%
AstraZenecaOutperform Votes
63
60.00%
Underperform Votes
42
40.00%

In the previous week, Novo Nordisk A/S had 17 more articles in the media than AstraZeneca. MarketBeat recorded 45 mentions for Novo Nordisk A/S and 28 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.13 beat Novo Nordisk A/S's score of 0.91 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
29 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
AstraZeneca
18 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Novo Nordisk A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$303.14B1.02$14.64B$3.3820.31
AstraZeneca$54.98B3.97$7.04B$2.4928.27

Novo Nordisk A/S presently has a consensus target price of $135.00, suggesting a potential upside of 96.68%. AstraZeneca has a consensus target price of $88.00, suggesting a potential upside of 25.04%. Given Novo Nordisk A/S's higher possible upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.38
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.10

Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S34.81% 84.68% 26.29%
AstraZeneca 13.01%32.23%12.31%

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. AstraZeneca pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$218.27B$6.46B$5.34B$8.46B
Dividend Yield2.96%2.65%5.29%4.18%
P/E Ratio31.148.6826.9019.78
Price / Sales3.97256.30409.22138.41
Price / Cash11.7965.8538.2534.64
Price / Book5.346.386.764.54
Net Income$7.04B$143.23M$3.22B$247.85M
7 Day Performance0.61%3.09%1.39%1.31%
1 Month Performance-1.85%2.84%9.42%9.43%
1 Year Performance-7.49%0.31%20.29%10.33%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
2.2147 of 5 stars
$70.87
+0.7%
$88.00
+24.2%
-8.1%$219.79B$54.98B31.3683,500Positive News
Short Interest ↑
NVO
Novo Nordisk A/S
4.6805 of 5 stars
$67.26
-1.3%
$135.00
+100.7%
-48.8%$301.83B$303.14B20.4454,400
NVS
Novartis
2.3664 of 5 stars
$112.77
+0.2%
$123.38
+9.4%
+12.2%$238.21B$53.22B19.18101,700Positive News
Short Interest ↓
SNY
Sanofi
3.5571 of 5 stars
$51.98
-1.0%
$63.33
+21.8%
+8.4%$131.32B$45.17B20.8891,600
GSK
GSK
1.9581 of 5 stars
$38.70
-0.6%
$40.58
+4.9%
-11.4%$79.84B$31.53B24.3490,100Trending News
Analyst Revision
TAK
Takeda Pharmaceutical
2.7773 of 5 stars
$14.58
+1.1%
N/A+11.2%$46.38B$4.58T36.4447,300Short Interest ↑
ARGX
argenx
3.255 of 5 stars
$587.61
+1.1%
$698.11
+18.8%
+57.3%$35.88B$2.58B-667.74650Positive News
ONC
Beigene
2.9392 of 5 stars
$241.43
+1.1%
$319.00
+32.1%
N/A$23.91B$4.18B-29.309,000
BNTX
BioNTech
2.6234 of 5 stars
$98.68
-0.4%
$141.73
+43.6%
+3.6%$23.72B$2.75B-46.993,080Analyst Forecast
Gap Down
TEVA
Teva Pharmaceutical Industries
2.6871 of 5 stars
$16.95
+0.0%
$24.43
+44.2%
+8.1%$19.21B$16.62B-11.6936,800Trending News
Analyst Upgrade
Short Interest ↑
Gap Down
SMMT
Summit Therapeutics
3.0962 of 5 stars
$25.85
+0.3%
$37.40
+44.7%
+989.5%$19.20B$700,000.00-92.32110Positive News

Related Companies and Tools


This page (NASDAQ:AZN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners